Lung Cancer Non-small Cell Stage IV research hub

Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC

This study compares using a drug called osimertinib alone, or osimertinib with focused radiation (SRS), for lung cancer that has spread to the brain. It's for people whose lung cancer has a specific genetic change (EGFR positive) and haven't had previous treatment for it.